Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma

Table 1 Clinical characteristics of the DLBCL patients according to DAPK1 methylation status

	Total (n = 71)	Unmethylated (n = 57)	Methylated (n = 14)	P value
Sex				0.136
Men	38	33	5
Women	33	24	9
Extranodal involvement				0.098
Yes	53	40	13
No	18	17	1
Stage				0.015
I–II	18	18	0
III–IV	53	39	14
Elevated LDH^b				1.000
Yes	51	40	11
No	17	14	3
B symptoms^b				1.000
Yes	20	16	4
No	49	39	10
IPI score^b				0.404
0–2	26	22	4
3–5	42	32	10
Performance score^a				1.000
0–2	62	50	12
3–4	9	7	2
Response^b				0.367
CR	51	43	8
PD/PR	10	7	3
Mors	4	2	2
Age at diagnosis (grouped)				0.959
<60 years	30	24	6
≥60 years	41	33	8
Age at diagnosis				0.653
Age, mean (range)	60 years (23–85)	60 years (23–85)	59 years (35–72)
Rituximab^b				1.000
Yes	59	47	12
No	11	9	2

LDH lactate dehydrogenase, IPI international prognostic index, CR complete response, PD progressive disease, PR partial response
^aEastern Cooperative Oncology Group
^bData was not available for all patients

ISSN: 1868-7083